These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28753889)

  • 41. Next generation sequencing search for uromodulin gene variants related with impaired renal function.
    Gómez J; Díaz-Corte C; Tranche S; Alvarez F; Iglesias S; Alonso B; Coto E
    Mol Biol Rep; 2015 Sep; 42(9):1353-8. PubMed ID: 26040415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of IL-10 Promoter Polymorphisms in Renal Cell Carcinoma.
    Chang WS; Liao CH; Tsai CW; Hu PS; Wu HC; Hsu SW; Ji HX; Hsiao CL; Bau DT
    Anticancer Res; 2016 May; 36(5):2205-9. PubMed ID: 27127124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.
    de Martino M; Taus C; Wessely IS; Lucca I; Hofbauer SL; Haitel A; Shariat SF; Klatte T
    DNA Cell Biol; 2015 Feb; 34(2):107-12. PubMed ID: 25415135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer.
    Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Serrano-Oviedo L; Gimenez-Bachs JM; Martínez-Sanchiz C; Segura-Martín M; Escribano J
    Urol Oncol; 2012; 30(6):864-70. PubMed ID: 21458313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma.
    de Martino M; Haitel A; Schatzl G; Klatte T
    J Urol; 2013 Oct; 190(4):1392-7. PubMed ID: 23517743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma.
    Chang WS; Liao CH; Miao CE; Wu HC; Hou LL; Hsiao CL; Ji HX; Tsai CW; Bau DT
    Anticancer Res; 2014 Oct; 34(10):5481-6. PubMed ID: 25275044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma.
    Piccoli MF; Figueira M; Andreoni C; Marumo JT; Schor N; Bellini MH
    Int Braz J Urol; 2007; 33(5):622-9. PubMed ID: 17980059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
    Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
    Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma.
    Hsueh YM; Lin YC; Chen WJ; Huang CY; Shiue HS; Pu YS; Chen CH; Su CT
    Toxicol Appl Pharmacol; 2017 Oct; 332():1-7. PubMed ID: 28733204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population.
    Obara W; Suzuki Y; Kato K; Tanji S; Konda R; Fujioka T
    Int J Urol; 2007 Jun; 14(6):483-7. PubMed ID: 17593089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development.
    Eikrem O; Beisland C; Hjelle K; Flatberg A; Scherer A; Landolt L; Skogstrand T; Leh S; Beisvag V; Marti HP
    PLoS One; 2016; 11(2):e0149743. PubMed ID: 26901863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population.
    Partyka A; Tupikowski K; Kolodziej A; Zdrojowy R; Halon A; Malkiewicz B; Dembowski J; Frydecka I; Karabon L
    Urol Oncol; 2016 Sep; 34(9):419.e13-9. PubMed ID: 27234378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. XRCC3 Thr241Met and XPD Lys751Gln gene polymorphisms and risk of clear cell renal cell carcinoma.
    Loghin A; Bănescu C; Nechifor-Boila A; Chibelean C; Orsolya M; Nechifor-Boila A; Tripon F; Voidazan S; Borda A
    Cancer Biomark; 2016; 16(2):211-7. PubMed ID: 26682510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of uromodulin as a new serum marker to predict decline in renal function.
    Leiherer A; Muendlein A; Saely CH; Brandtner EM; Geiger K; Fraunberger P; Drexel H
    J Hypertens; 2018 Jan; 36(1):110-118. PubMed ID: 28858977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
    Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
    Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.
    Gudbjartsson DF; Holm H; Indridason OS; Thorleifsson G; Edvardsson V; Sulem P; de Vegt F; d'Ancona FC; den Heijer M; Wetzels JF; Franzson L; Rafnar T; Kristjansson K; Bjornsdottir US; Eyjolfsson GI; Kiemeney LA; Kong A; Palsson R; Thorsteinsdottir U; Stefansson K
    PLoS Genet; 2010 Jul; 6(7):e1001039. PubMed ID: 20686651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
    Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
    Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
    Thompson RH; Cheville JC; Lohse CM; Webster WS; Zincke H; Kwon ED; Frank I; Blute ML; Leibovich BC
    Cancer; 2005 Jul; 104(1):53-60. PubMed ID: 15895375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined Genotype Analyses of Precursor miRNA196a2 and 499a Variants with Hepatic and Renal Cancer Susceptibility a Preliminary Study.
    Toraih EA; Fawz MS; Elgazzaz MG; Hussein MH; Shehata RH; Daoud HG
    Asian Pac J Cancer Prev; 2016; 17(7):3369-75. PubMed ID: 27509977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.